Heart transplantation for COVID-19 myopathy in the United States.
J Heart Lung Transplant
; 42(4): 447-450, 2023 04.
Article
in English
| MEDLINE | ID: covidwho-2230368
ABSTRACT
Evidence on characteristics and outcomes of patients undergoing heart transplantation for coronavirus disease 2019 (COVID-19) associated cardiomyopathy is limited to case reports. Of all 6,332 patients aged ≥18 years undergoing heart transplantation from July 2020 through May 2022 in the United Network for Organ Sharing database, 12 (0.2%) patients had COVID-19 myocarditis and 98 (1.6%) patients with the same level of care had non-COVID-19 myocarditis. Their median age was 49 (range 19-74) years. All patients were hospitalized in the intensive care unit and 92.7% (n = 102) were on life support prior to transplantation. No patients with COVID-19 myocarditis required ventilation while waitlisted. Survival free from graft failure was 100% among COVID-19 patients and 88.5% among non-COVID-19 patients at a median of 257 (range 0-427) days post-transplant. These findings indicate that transplantation is rarely performed for COVID-19 related cardiomyopathy in the United States, yet early outcomes appear favorable in select patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Heart Transplantation
/
COVID-19
/
Cardiomyopathies
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
/
Young adult
Country/Region as subject:
North America
Language:
English
Journal:
J Heart Lung Transplant
Journal subject:
Cardiology
/
Transplantation
Year:
2023
Document Type:
Article
Affiliation country:
J.healun.2022.09.020
Similar
MEDLINE
...
LILACS
LIS